Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
The Longevity Fund, established in 2011 by Laura Deming, is a venture capital firm located in the United States. The firm focuses on funding companies that develop drugs targeting age-related diseases, aiming to extend healthy human lifespan. Since its inception, The Longevity Fund has been instrumental in supporting early longevity companies that have successfully gone public, marking its significance in the biotech sector.
Currently, the fund manages approximately $37 million in assets and has invested in a portfolio of 15 companies. The Longevity Fund is transitioning to a new fund named age1, which continues its mission in the longevity sector while maintaining a commitment to innovative drug development approaches. The firm has a notable history of backing companies that challenge traditional biotech norms, emphasizing the importance of founder-driven initiatives.
The Longevity Fund primarily invests in the longevity sector, particularly in companies developing therapeutics for age-related diseases. The firm targets early-stage investments, specifically in the Seed, Series A, and Series B stages, with check sizes ranging from $0 to $1 million. The organization emphasizes the significance of founder-driven companies, believing that mission-oriented entrepreneurs are essential for building successful ventures in the longevity biotech space.
Investment criteria include a focus on innovative drug development approaches that challenge conventional biotech practices. The Longevity Fund seeks to support companies that are not only developing therapeutics but also advancing technologies that can significantly impact the treatment of age-related diseases. The firm operates primarily within the United States, although its relevance extends globally within the biotech community.
The Longevity Fund's portfolio includes a diverse range of companies focused on various aspects of longevity and age-related diseases. Notable portfolio companies include:
Laura Deming: Founder of The Longevity Fund, Laura has been a prominent figure in the longevity biotech space since founding the firm in 2011. She focuses on human life extension and using biological research to mitigate the effects of aging. Laura's leadership has been instrumental in the fund's success and its transition to the new fund, age1.
Alex Colville: General Partner at age1, Alex has a Ph.D. in biology of aging from Stanford University. He previously managed biotech investing and philanthropy around aging and now leads age1, which builds on The Longevity Fund's legacy. His expertise in longevity and commitment to supporting founder-led companies are key to the fund's mission.
Lily Clayton: Listed among employees at The Longevity Fund, Lily's role is not fully detailed in the available sources, but she is recognized for her contributions to the firm's mission and support for portfolio companies.
To pitch The Longevity Fund, founders should visit the fund's website at longevity.vc and submit their information through the provided channels. It is essential to include a clear explanation of the company's mission, the problem it addresses, and how it aligns with the fund's focus on longevity.
Founders are encouraged to provide detailed information about their team, the scientific basis of their approach, and any preliminary results or traction. The fund values founder-driven initiatives and innovative drug development approaches, so pitches should reflect these priorities. Response times may vary, but founders can expect to hear back regarding their submissions.
The Longevity Fund initiated an accelerator program in 2018 to support founder-driven companies in the longevity sector. This program is designed to test the hypothesis that founder-led initiatives are essential for advancing innovations in longevity. Eligibility details and application processes for the program can be found on the fund's website.
In September 2023, The Longevity Fund announced the launch of its new fund, age1, which continues its mission to support innovative approaches in the longevity sector. This new fund is built on the foundation of The Longevity Fund's decade of work and focuses on founder-led longevity biotech companies.
Additionally, The Longevity Fund has maintained its accelerator program since 2018, designed to foster founder-driven companies in the longevity field. This program aims to validate the importance of such companies in advancing longevity innovations.
What are The Longevity Fund's investment criteria?
The Longevity Fund invests in founder-led companies developing therapeutics for age-related diseases, primarily in the Seed, Series A, and Series B stages. The fund emphasizes innovative drug development approaches that challenge traditional biotech norms.
How can I pitch to The Longevity Fund?
Founders can pitch their companies by visiting the fund's website at longevity.vc and submitting their information through the provided channels. It is recommended to include a clear explanation of the company's mission and how it aligns with the fund's focus on longevity.
What makes The Longevity Fund different from other VCs?
The Longevity Fund specifically targets the longevity biotech sector and emphasizes the importance of founder-driven companies. The firm has a history of backing early longevity companies that have gone public, showcasing its commitment to this niche.
What is the geographic scope of The Longevity Fund?
The Longevity Fund primarily invests in companies based in the United States, but its relevance extends globally within the biotech community.
What is the typical check size for investments?
The Longevity Fund typically invests between $0 and $1 million in its portfolio companies, focusing on early-stage funding.
What kind of support does The Longevity Fund provide to its portfolio companies?
The fund provides strategic guidance and support tailored to the unique challenges of the longevity biotech sector, emphasizing the importance of founder-driven initiatives.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.